PATENT CLAIM ANALYSIS

Application Number: 16068218
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "135100"]

Abstract:
The present invention relates to methods of treating Type 2 diabetes (T2D), comprising administering to a patient an effective amount of an isolated antagonistic antigen binding protein that specifically binds to the human glucagon receptor, either as monotherapy, or in combination with one or more antidiabetic medications.

Claim (Index 22):
A method according to  claim 21 , wherein the therapeutically effective amount of the isolated antagonistic antibody is selected from the group consisting of: about 0.1 to about 0.2 mg/kg, about 0.2 to about 0.4 mg/kg, about 0.4 to about 0.6 mg/kg, about 0.6 to about 0.8 mg/kg, about 0.8 to about 1.0 mg/kg, about 1.0 to about 1.2 mg/kg, about 1.2 to about 1.4 mg/kg, about 1.4 to about 1.6 mg/kg, about 1.6 to about 1.8 mg/kg, about 1.8 to about 2.0 mg/kg, about 2.0 to about 2.2 mg/kg, about 2.2 to about 2.4 mg/kg, about 2.4 to about 2.6 mg/kg, about 2.6 to about 2.8 mg/kg, and about 2.8 to about 3.0 mg/kg.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 95.0
- Lexical Diversity: 1.15217
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15316866', '14855274', '13900275', '15415672', '14821652']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7884757732284636
- 35 USC 102 Novelty (BERT): 0.5164222688193072
- Combined Prediction Score: 0.7612704227875481
- Mean Citation Score: 290.64235
- Max Citation Score: 296.55685
- Similarity Product: 187.2259470939636

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test